Big Pharma’s about to lose $200 billion in drug revenue — and the race to replace it is reshaping biotech worldwide.
On this episode, Robert Darwin, Senior Partner at global law firm Sidley Austin, joins us to explore:
Why pharma’s writing massive M&A checks again
How China is emerging as a leading hub for drug innovation
Europe’s strengths—and where it still needs to catch up
What’s stalled IPO markets — and what could kickstart them again
Where the new biotech funding is really coming from (it might surprise you)
Plus: Robert offers his straightforward insights on FDA developments, pricing politics, and why today’s science feels straight out of “Star Trek.”
If you’re in biotech, finance, or just curious about the industry’s future, this conversation is for you.
🎧 Hit play now and stay ahead of the curve.